Ser141
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Phosphorylation Site Page: > Ser141  -  DAPP1 (human)

Site Information
EEPsIyEsVRVHTAM   SwissProt Entrez-Gene
Blast this site against: NCBI  SwissProt  PDB 
Site Group ID: 14510068

In vivo Characterization
Methods used to characterize site in vivo:
immunoprecipitation ( 1 ) , mass spectrometry ( 2 , 3 , 4 , 5 ) , mutation of modification site ( 1 ) , phospho-antibody ( 1 ) , western blotting ( 1 )
Disease tissue studied:
gastric carcinoma, surrounding tissue ( 5 ) , leukemia ( 1 ) , T cell leukemia ( 1 ) , lung cancer ( 4 ) , non-small cell lung cancer ( 4 ) , non-small cell lung adenocarcinoma ( 4 )
Relevant cell line - cell type - tissue:
CD4+ (T lymphocyte) ( 1 ) , Jurkat (T lymphocyte) ( 1 , 3 ) , lung ( 4 ) , stomach ( 5 )

Upstream Regulation
Regulatory protein:
CD3E (human) ( 1 )
Treatments:
calyculin_A ( 1 )

Downstream Regulation
Effects of modification on DAPP1:
enzymatic activity, induced ( 1 ) , molecular association, regulation ( 1 ) , phosphorylation ( 1 )
Effects of modification on biological processes:
signaling pathway regulation ( 1 )
Induce interaction with:
PLCG1 (human) ( 1 )

References 

1

Rouquette-Jazdanian AK, et al. (2012) LAT-Independent Erk Activation via Bam32-PLC-γ1-Pak1 Complexes: GTPase-Independent Pak1 Activation. Mol Cell 48, 298-312
22981863   Curated Info

2

Possemato A (2012) CST Curation Set: 13559; Year: 2012; Biosample/Treatment: cell line, mixTMT(A549,H3255,MKN45,H3122,,H1703,H1650)/untreated; Disease: -; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

3

Zhou J (2011) CST Curation Set: 12347; Year: 2011; Biosample/Treatment: cell line, Jurkat/calyculin_A & pervanadate; Disease: T cell leukemia; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[STY]
Curated Info

4

Ren H (2011) CST Curation Set: 11772; Year: 2011; Biosample/Treatment: tissue, lung/untreated; Disease: non-small cell lung adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info

5

Ren H (2009) CST Curation Set: 8023; Year: 2009; Biosample/Treatment: tissue, gastrointestinal tract/untreated; Disease: gastric cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991
Curated Info